Is Kenvue Stock Outperforming the Nasdaq?
New Jersey-based Kenvue Inc. (KVUE) is a consumer health company operating across the Americas, Europe, EMEA, and the Indo-Pacific. It operates through Self Care, Skin Health and Beauty, and Essential Health segments. With a market cap of $41.3 billion, Kenvue owns several well-known brands like Listerine, BAND-AID, Tylenol, Neutrogena, and more.
Companies worth $10 billion or more are generally described as "large-cap stocks." Kenvue fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the consumer health space. As the world’s largest pure-play consumer health company by revenue, Kenvue continues to expand its presence in the industry.
Kenvue touched its 52-week high of $25.17 on May 8 and is currently trading 13.2% below that peak. Over the past three months, KVUE stock has plunged nearly 7%, significantly underperforming the Nasdaq Composite’s ($NASX) 12.5% surge during the same time frame.
However, KVUE’s performance has remained much more impressive over the longer term. KVUE stock has gained 2.3% on a YTD basis and 18.3% over the past 52 weeks, outpacing NASX’s 1.6% uptick in 2025 and 13.1% surge over the past year.
To confirm the bullish trend and recent downturn, KVUE has traded mostly above its 200-day moving average since early August 2024, with some fluctuations and has fallen below its 50-day and 200-day moving averages since the start of June.
Kenvue’s stock prices gained 4.1% following the release of its better-than-expected Q1 results on May 8. Due to a dip in organic sales and currency headwinds, the company’s net sales for the quarter dropped 3.9% year-over-year to $3.7 billion. However, the figure surpassed the consensus estimate by 1.7%. Meanwhile, Kenvue’s adjusted EPS dropped 14.3% year-over-year to $0.24, but surpassed the Street’s expectations by 9.1%, which boosted investor confidence.
While Kenvue has outpaced its peer Unilever PLC’s (UL) 13.2% surge over the past 52 weeks, it has notably lagged behind UL’s 11% gains in 2025.
Nevertheless, analysts remain moderately optimistic about the stock’s prospects. Among the 15 analysts covering the KVUE stock, the consensus rating is a “Moderate Buy.” Its mean price target of $24.50 suggests a 12.1% upside potential from current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.